|
業務類別
|
Biotechnology |
|
業務概覽
|
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role. |
| 公司地址
| 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402 |
| 電話號碼
| +1 650 561-8600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sagimet.com |
| 員工數量
| 14 |
| Dr. Eduardo Bruno Martins, D.Phil.,M.D. |
Chief Medical Officer |
美元 475.00K |
30/04/2025 |
| Mr. David Happel |
Director, Chief Executive Officer and President |
美元 582.00K |
30/04/2025 |
| Mr. Thierry Chauche |
Chief Financial Officer and Principal Accounting Officer |
美元 314.55K |
30/04/2025 |
| Ms. Elizabeth Rozek |
General Counsel and Chief Compliance Officer |
-- |
30/04/2025 |
|
|
| Dr. Beth C. Seidenberg,M.D. |
Independent Director |
30/04/2025 |
| Mr. David Happel |
Director, Chief Executive Officer and President |
30/04/2025 |
| Mr. Timothy P. Walbert |
Independent Director |
30/04/2025 |
| Mr. George Kemble, PhD |
Executive Chairman of the Board |
30/04/2025 |
| Ms. Elizabeth Grammer, Esq. |
Independent Director |
30/04/2025 |
| Dr. Anne M. Phillips, M.D. |
Independent Director |
30/04/2025 |
| Ms. Jennifer Ann Jarrett |
Independent Director |
30/04/2025 |
|
|
|
|
